Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Dithiazanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 2/20 | 1.00 |
| ▸ | CTNNB1 | P35222 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL7761426 | 1.00 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AHTT | |
| Dithiazanine SCHEMBL29369795 | 1.00 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AHTT | |
| Iodide SCHEMBL139369 | 1.00 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AHTT | |
| Iodide SCHEMBL29393130 | 1.00 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AHTT | |
| Dithiazanine SCHEMBL22877 | 1.00 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AHTT | |
| Iodide SCHEMBL335663 | 1.00 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AHTT | |
| Dithiazanine SCHEMBL142280 | 1.00 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AHTT | |
| Dithiazanine SCHEMBL29459605 | 1.00 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AHTT | |
| SCHEMBL13898198 | 0.99 | KMT2A (1.00) | MEN1KMT2ANPC1RAB9AHTT | |
| Dithiazanine SCHEMBL1567134 | 0.99 | KMT2A (1.00) | MEN1KMT2ANPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-16 | — | — | US | disclosed |
| US-20190033319-A1 | BINDING DOMAIN MAPPING | George Mason Research Foundation, Inc. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10126304-B2 | Binding domain mapping | George Mason Research Foundation, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20150338417-A1 | BINDING DOMAIN MAPPING | GEORGE MASON UNIVERSITY | 2015-11-26 | — | — | US | disclosed |
| WO-2014113433-A1 | BINDING DOMAIN MAPPING | GEORGE MASON UNIVERSITY (US) | 2014-07-24 | — | — | WO | disclosed |
| US-8132198-B2 | Point-of-sale enablement of optical storage media | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2012-03-06 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100251276-A1 | POINT-OF-SALE ENABLEMENT OF OPTICAL STORAGE MEDIA | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2010-09-30 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080184282-A1 | POINT-OF-SALE ENABLEMENT OF OPTICAL STORAGE MEDIA | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10126304-B2 | Binding domain mapping | SNRPE, HSPBP1, CNBP | MEN1 3941/4885KMT2A 3866/4885NPC1 3663/4885 |
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | SYNCRIP, FUS, SARS1 | MEN1 2597/4885KMT2A 1988/4885NPC1 2739/4885 |
| US-20190033319-A1 | BINDING DOMAIN MAPPING | SNRPE, HSPBP1, CNBP | MEN1 3941/4885KMT2A 3866/4885NPC1 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.